Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapse Multiple Myeloma: early-phase trial registry
6 of 8 indexed Relapse Multiple Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 6 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Relapse Multiple Myeloma: 8 US clinical trials tracked, 6 recruiting.
Relapse Multiple Myeloma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is David Avigan, running 1 of these trials.
Enrollment posture brief
Registry condition relapse-multiple-myeloma
OPEN 6 | RECR 75% | LATE 0 | EARLY 8 | RANK #2176 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adolescent Idiopathic Scoliosis (75% recruiting · 8 trials)
Relapse Multiple Myeloma lists 6 open slots (75% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapse Multiple Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapse Multiple Myeloma is recruiting above its size-band peers.
6 of 8 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Relapse Multiple Myeloma trials is spread across many organizations.
David Avigan accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Relapse Multiple Myeloma trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.
-
Relapse Multiple Myeloma research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
Multiple Myeloma Research Consortium
NCT06171685
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
Janssen Research & Development
NCT06500884
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
University of Chicago
NCT05789303
Elranatamab in R/R Multiple Myeloma
Massachusetts General Hospital
NCT06138275
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
Medical College of Wisconsin
NCT07093554
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
David Avigan
NCT06799026
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT05431608
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
NCT04302324
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapse Multiple Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapse Multiple Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapse Multiple Myeloma page
8 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Relapse Multiple Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- David Avigan sponsors the most Relapse Multiple Myeloma trials on record, review their full trial history before evaluating a specific study. See David Avigan's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapse Multiple Myeloma condition card totals 8 registered trials; most-linked intervention Talquetamab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.